{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=70", "query": { "condition": "Melanoma Neoplasms", "page": 70 }, "page_size": 10 }, "pagination": { "page": 70, "page_size": 10, "total_count": 2209, "total_pages": 221, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=71&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=69&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T00:19:11.694Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02012699", "title": "Integrated Cancer Repository for Cancer Research", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Cancer", "Thyroid Cancer", "Lung Cancer", "Esophageal Cancer", "Thymus Cancer", "Colon Cancer", "Rectal Cancer", "Gastrointestinal Stromal Tumors", "Anal Cancer", "Bile Duct Cancer", "Duodenal Cancer", "Gallbladder Cancer", "Gastric Cancer", "Liver Cancer", "Small Intestine Cancer", "Peritoneal Surface Malignancies", "Familial Adenomatous Polyposis", "Lynch Syndrome", "Bladder Cancer", "Kidney Cancer", "Penile Cancer", "Prostate Cancer", "Testicular Cancer", "Ureter Cancer", "Urethral Cancer", "Hypopharyngeal Cancer", "Laryngeal Cancer", "Lip Cancer", "Oral Cavity Cancer", "Nasopharyngeal Cancer", "Oropharyngeal Cancer", "Paranasal Sinus Cancer", "Nasal Cavity Cancer", "Salivary Gland Cancer", "Skin Cancer", "Central Nervous System Tumor", "Central Nervous System Cancer", "Mesothelioma", "Breast Cancer", "Leukemia", "Melanoma", "Sarcoma", "Unknown Primary Tumor", "Multiple Myeloma", "Ovarian Cancer", "Endometrial Cancer", "Vaginal Cancer", "Neuroendocrine Tumors", "Plasma Cell Dyscrasia", "Healthy Control" ], "interventions": [], "intervention_types": [], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "19 Years to 110 Years" }, "enrollment_count": 999999, "start_date": "2013-11-01", "completion_date": "2099-12", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-31T00:19:11.694Z", "location_count": 42, "location_summary": "Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more", "locations": [ { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Manchester", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "DeLand", "state": "Florida" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02012699" }, { "nct_id": "NCT03894618", "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck", "Melanoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Squamous Cell Carcinoma of the Anus", "Squamous Cell Carcinoma of the Cervix", "Squamous Cell Carcinoma of the Skin", "Renal Cell Carcinoma", "Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "Mismatch Repair Deficient or MSI-High Solid Tumors" ], "interventions": [ { "name": "SL-279252", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shattuck Labs, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2019-03-26", "completion_date": "2023-05-04", "has_results": true, "last_update_posted_date": "2025-04-02", "last_synced_at": "2026-10-31T00:19:11.694Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03894618" }, { "nct_id": "NCT03190174", "title": "Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ewing Sarcoma", "PEComa", "Epithelioid Sarcoma", "Desmoid Tumor", "Chordoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "Classical Hodgkin Lymphoma", "Colorectal Cancer", "MTOR Activating Mutation" ], "interventions": [ { "name": "Nab-Rapamycin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sarcoma Oncology Research Center, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 34, "start_date": "2017-08-24", "completion_date": "2021-12-02", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-10-31T00:19:11.694Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03190174" }, { "nct_id": "NCT01519323", "title": "BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 6, "start_date": "2013-01", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2016-10-10", "last_synced_at": "2026-10-31T00:19:11.694Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Saint Petersburgh, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Saint Petersburgh", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01519323" }, { "nct_id": "NCT03993379", "title": "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Unresectable or Metastatic Melanoma" ], "interventions": [ { "name": "CX-072", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytomX Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-11-20", "completion_date": "2020-05-21", "has_results": true, "last_update_posted_date": "2025-12-26", "last_synced_at": "2026-10-31T00:19:11.694Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03993379" }, { "nct_id": "NCT00089362", "title": "Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Gastric Cancer", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Melanoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Ovarian Epithelial Cancer", "Recurrent Prostate Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Basal Cell Carcinoma of the Lip", "Stage III Colon Cancer", "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage III Gastric Cancer", "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage III Lymphoepithelioma of the Nasopharynx", "Stage III Lymphoepithelioma of the Oropharynx", "Stage III Melanoma", "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Ovarian Epithelial Cancer", "Stage III Renal Cell Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Melanoma", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Ovarian Epithelial Cancer", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "alvespimycin hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-10", "last_synced_at": "2026-10-31T00:19:11.694Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089362" }, { "nct_id": "NCT04562129", "title": "IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage IV", "Inoperable Disease" ], "interventions": [ { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2020-09-24", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-31T00:19:11.694Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04562129" }, { "nct_id": "NCT05764395", "title": "Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma", "Refractory Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Rigosertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-05-09", "completion_date": "2026-03-13", "has_results": true, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-31T00:19:11.694Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05764395" }, { "nct_id": "NCT03132922", "title": "MAGE-A4ᶜ¹º³²T for Multi-Tumor", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Cancer", "Melanoma", "Head and Neck Cancer", "Ovarian Cancer", "Non-Small Cell Lung Cancer", "Esophageal Cancer", "Gastric Cancer", "Synovial Sarcoma", "Myxoid Round Cell Liposarcoma", "Gastroesophageal Junction" ], "interventions": [ { "name": "Autologous genetically modified MAGE-A4ᶜ¹º³²T cells", "type": "GENETIC" }, { "name": "Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation", "type": "RADIATION" } ], "intervention_types": [ "GENETIC", "RADIATION" ], "sponsor": "USWM CT, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 71, "start_date": "2017-05-15", "completion_date": "2032-09", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-31T00:19:11.694Z", "location_count": 10, "location_summary": "Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03132922" }, { "nct_id": "NCT01416831", "title": "Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Radiation therapy and high-dose IL-2", "type": "OTHER" }, { "name": "High-dose IL-2", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2011-07-01", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-31T00:19:11.694Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01416831" } ] }